source
- Endpoints Weekly previews ASCO coverage, discusses AI in research and shifting immunotherapy strategiesThe weekly newsletter returns with a team of reporters stationed in Chicago for the upcoming ASCO meeting. It promises on‑the‑ground insights from the conference. One focus will be the role of art…
- Bristol Myers reports Phase 3 data showing mezigdomide extends survival in relapsed multiple myelomaBristol Myers Squibb presented Phase 3 results for its experimental multiple myeloma drug mezigdomide at the American Society of Clinical Oncology meeting. The study evaluated mezigdomide combined…